Equities

Sight Sciences Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
SGHT:NSQ

Sight Sciences Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)5.44
  • Today's Change-0.335 / -5.81%
  • Shares traded72.12k
  • 1 Year change+104.32%
  • Beta2.4077
Data delayed at least 15 minutes, as of Feb 11 2026 16:21 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.

  • Revenue in USD (TTM)76.05m
  • Net income in USD-46.11m
  • Incorporated2010
  • Employees216.00
  • Location
    Sight Sciences Inc4040 Campbell Ave,, Suite 100MENLO PARK 94025United StatesUSA
  • Phone+1 (415) 889-0550
  • Fax+1 (302) 655-5049
  • Websitehttps://www.sightsciences.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Orchestra Biomed Holdings Inc2.82m-75.10m235.46m70.00--5.38--83.55-1.82-1.820.06760.77460.03130.657833.7540,257.14-83.39---104.85--93.01---2,665.05--4.72--0.2451---4.42---24.23------
908 Devices Inc57.64m-57.10m245.03m246.00--1.79--4.25-1.61-0.11161.623.770.31231.764.17234,296.80-30.94-18.01-37.82-19.6749.3552.89-99.07-78.453.12--0.00--18.7227.11-98.37--8.96--
Applied Energetics Inc1.15m-13.02m263.67m21.00------228.66-0.0599-0.05990.0053-0.00330.3065--7.7054,908.57-345.27-139.08-454.84-208.3658.5860.61-1,126.59-473.16---------7.78---24.71--51.42--
Shoulder Innovations Inc41.63m-34.45m271.74m61.00--1.84--6.53-1.91-1.912.247.18----------------76.67---82.75--9.80--0.0913--64.07---50.85------
Simulations Plus Inc78.68m-64.25m281.45m212.00--2.21--3.58-3.20-3.203.906.310.4701--4.28371,113.20-38.39-2.50-40.84-2.6559.6069.96-81.66-7.29----0.00--13.0913.74-750.17--7.57-24.21
Trubridge Inc349.88m5.42m285.02m3.20k51.201.588.890.81460.37090.370924.2312.020.8737257.086.17109,338.401.39-0.91071.60-1.0353.1650.131.59-1.141.902.400.4768--0.9464.5256.05--61.10--
Quanterix Corp130.20m-95.66m285.87m471.00--0.9083--2.20-2.33-2.333.216.740.30451.444.06276,439.50-22.37-13.18-25.81-14.5351.5356.14-73.47-45.092.31--0.0029--12.3019.36-35.89---20.86--
Evolent Health Inc2.05bn-180.89m304.67m4.50k--0.3617--0.1483-1.57-1.5717.857.550.829--5.17456,456.00-5.17-5.93-6.41-8.0018.4221.07-6.24-7.16--0.1890.5572--30.0930.0434.31---6.87--
Sight Sciences Inc76.05m-46.11m305.07m216.00--4.71--4.01-0.8955-0.89551.471.230.58541.426.71352,092.60-35.49-35.50-39.37-38.5386.8382.63-60.63-94.208.93-76.380.384---1.4727.897.27---10.54--
Carlsmed Inc-100.00bn-100.00bn320.18m100.00--3.00----------4.01------------------------11.91--0.1265--97.16---31.49------
Owlet Inc99.64m-42.45m322.42m80.00------3.24-2.75-2.756.08-2.341.523.804.361,245,500.00-60.37-64.44-244.32-331.1152.0644.29-39.68-58.720.9074-2.48----44.529.4054.08---17.23--
Rxsight Inc142.09m-35.73m337.57m498.00--1.22--2.38-0.8782-0.87823.506.720.45911.405.74285,313.30-11.54-19.50-12.45-21.5074.9857.17-25.15-52.0011.44--0.0004--57.09128.6143.52--5.89--
Senseonics Holdings Inc29.30m-63.77m338.31m117.00--4.32--11.55-1.65-1.650.75651.920.2483.625.22250,410.30-53.98-71.11-70.98-94.7541.11-14.81-217.65-594.095.93-29.180.3109--0.36621.08-30.18--16.46--
Delcath Systems Inc79.60m1.20m356.67m96.001,160.923.11255.864.480.00870.00872.103.251.021.267.70829,197.901.54-94.541.90-143.9786.2981.311.50-339.8513.71--0.00--1,701.7088.1044.66--87.69--
Data as of Feb 11 2026. Currency figures normalised to Sight Sciences Inc's reporting currency: US Dollar USD

Institutional shareholders

23.31%Per cent of shares held by top holders
HolderShares% Held
Long Focus Capital Management LLCas of 30 Sep 20253.19m6.04%
BlackRock Fund Advisorsas of 30 Sep 20252.32m4.39%
The Vanguard Group, Inc.as of 31 Dec 20251.69m3.20%
Americana Partners LLCas of 31 Dec 20251.38m2.61%
The B Group, Inc.as of 30 Sep 2025930.00k1.76%
Geode Capital Management LLCas of 30 Sep 2025853.16k1.61%
SSgA Funds Management, Inc.as of 30 Sep 2025664.00k1.26%
Acadian Asset Management LLCas of 30 Sep 2025476.49k0.90%
Prosight Management LPas of 30 Sep 2025439.94k0.83%
Renaissance Technologies LLCas of 30 Sep 2025375.80k0.71%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.